WO2005117930A3 - Use of thioredoxin measurements for diagnostics and treatments - Google Patents

Use of thioredoxin measurements for diagnostics and treatments Download PDF

Info

Publication number
WO2005117930A3
WO2005117930A3 PCT/US2005/019523 US2005019523W WO2005117930A3 WO 2005117930 A3 WO2005117930 A3 WO 2005117930A3 US 2005019523 W US2005019523 W US 2005019523W WO 2005117930 A3 WO2005117930 A3 WO 2005117930A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
thioredoxin
methods
diagnostics
treatments
Prior art date
Application number
PCT/US2005/019523
Other languages
French (fr)
Other versions
WO2005117930A2 (en
Inventor
Paul A Marks
Johanna Ungerstedt
Original Assignee
Sloan Kettering Inst Cancer
Paul A Marks
Johanna Ungerstedt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer, Paul A Marks, Johanna Ungerstedt filed Critical Sloan Kettering Inst Cancer
Publication of WO2005117930A2 publication Critical patent/WO2005117930A2/en
Publication of WO2005117930A3 publication Critical patent/WO2005117930A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to methods for monitoring patient response to histone deacetylase inhibitors (e.g., suberoylanilide hydroxamic acid (SAHA)) or other therapeutic agents by measuring the level of thioredoxin in body fluids, tissues, and/or cells, such as peripheral blood mononuclear cells, plasma, or serum. The invention also relates to methods of monitoring and/or assisting with the diagnosis of a wide variety of thioredoxin-related diseases and conditions, such as inflammatory diseases, allergic diseases, autoimmune diseases, diseases associated with oxidative stress or diseases characterized by cellular hyperproliferation.
PCT/US2005/019523 2004-06-04 2005-06-03 Use of thioredoxin measurements for diagnostics and treatments WO2005117930A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57708904P 2004-06-04 2004-06-04
US60/577,089 2004-06-04

Publications (2)

Publication Number Publication Date
WO2005117930A2 WO2005117930A2 (en) 2005-12-15
WO2005117930A3 true WO2005117930A3 (en) 2009-04-02

Family

ID=35463340

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/019523 WO2005117930A2 (en) 2004-06-04 2005-06-03 Use of thioredoxin measurements for diagnostics and treatments

Country Status (1)

Country Link
WO (1) WO2005117930A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008013589A2 (en) 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Treatment of ras-expressing tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
WO2008046909A1 (en) * 2006-10-20 2008-04-24 Dkfz Deutsches Krebsforschungszentrum The histone deacetylase inhibitor helminthosporium carbonum toxin for suppressing malignant qualities of neuroblastoma cells
CN107090482A (en) 2006-12-29 2017-08-25 细胞基因公司 Prepare Romidepsin
EP1990423A1 (en) * 2007-05-10 2008-11-12 Pangaea Biotech, S.A. Method of determining the time to progression of non small cell lung cancer after chemotherapy based on thioredoxin expression
RU2016149485A (en) 2010-07-12 2018-10-31 Селджин Корпорейшн SOLID FORMS OF ROMIDEPSIN AND THEIR APPLICATION
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
US11002739B2 (en) 2016-09-13 2021-05-11 E&S Healthcare Co., Ltd. Monoclonal antibody specifically binding to thioredoxin 1, and use thereof
AU2018349387B2 (en) 2017-10-12 2022-05-19 E&S Healthcare Co., Ltd. Thioredoxin 1 epitope and monoclonal antibody specifically binding thereto

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235588A1 (en) * 2002-02-15 2003-12-25 Richon Victoria M. Method of treating TRX mediated diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235588A1 (en) * 2002-02-15 2003-12-25 Richon Victoria M. Method of treating TRX mediated diseases

Also Published As

Publication number Publication date
WO2005117930A2 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
WO2005117930A3 (en) Use of thioredoxin measurements for diagnostics and treatments
Høier et al. The effect of passive movement training on angiogenic factors and capillary growth in human skeletal muscle
Briguori et al. Novel biomarkers for contrast-induced acute kidney injury
Kashyap et al. Different antioxidants status, total antioxidant power and free radicals in essential hypertension
Bjugstad et al. Oxidation-reduction potential as a biomarker for severity and acute outcome in traumatic brain injury
US20130309328A1 (en) Method of determining vasoreactivity using inhaled nitric oxide
Chi et al. Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation
WO2008116150A3 (en) Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
WO2007086986A3 (en) Novel application of biosensors for diagnosis and treatment of disease
WO2006102536A3 (en) Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
Rosolowsky et al. Between hyperfiltration and impairment: demystifying early renal functional changes in diabetic nephropathy
Mulè et al. Relationships between mild hyperuricaemia and aortic stiffness in untreated hypertensive patients
JP2010529468A5 (en)
Goto et al. Circadian blood pressure rhythm is disturbed by nephrectomy
HK1107148A1 (en) Use of anti-robo1 antibody in manufacturing a medicament for treating cancer and related diagnosis kit
Dinc et al. Methylene blue inhibits the inflammatory process of the acetic acid-induced colitis in rat colonic mucosa
Gawron-Skarbek et al. Physical activity, aerobic capacity, and total antioxidant capacity in healthy men and in men with coronary heart disease
Bet et al. Depleted nitrite and enhanced oxidative stress in urolithiasis
DyabAllawi et al. Neutrophil gelatinase associated lipocalin (NGAL) in early detection of nephropathy in type 2 diabetic Iraqi patients
WO2012167887A8 (en) Diagnostic use of prosomatostatin
WO2006124866A3 (en) Free human serum ige immunoenzymetric assay and methods of use
Mahajan et al. Uric acid a better scavenger of free radicals than vitamin C in rheumatoid arthritis
JP2012506558A5 (en)
Amer et al. Relationship between ECG pattern, Heat Shock Protein 70 and oxidative biomarkers among workers occupationally exposed to noise
Kawakami et al. The effects of intermittent or continuous exercise on renal haemodynamics during moderate-intensity exercise

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase